Cassava Sciences, Inc. (SAVA)

Market Cap	122.68M
Revenue (ttm)	n/a
Net Income (ttm)	-17.66M
Shares Out	48.11M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,085,628
Open	2.780
Previous Close	2.700
Day's Range	2.550 - 2.800
52-Week Range	2.230 - 42.200
Beta	-0.95
Analysts	Buy
Price Target	111.50 (+4,272.55%)
Earnings Date	Mar 7, 2025

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SAVA
• Website: https://www.cassavasciences.com

Analyst Forecast

According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is $111.5, which is an increase of 4,272.55% from the latest price.

Price Target

$111.5

(4,272.55% upside)

Analyst Consensus: Buy